M D Anderson Cancer Center
Houston, Texas, 77030, United States
Location status: Recruiting
Location contact
Ajay Sheshadri
CONTACT
NCT Number: NCT05041140
This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD).
The primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.
A secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Houston, Texas, 77030, United States
Location status: Recruiting
Ajay Sheshadri
CONTACT
The primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.
A secondary objective is to assess the differences in 129-Xe MRI characteristics between patients with and without OS progression at 6 months after enrollment. Other secondary objectives include the assessment of the relationship of VDP, barrier defects (continuous variable), and circulation defects (continuous variable) with pulmonary function, quantitative CT measurements, SGRQ, and SF-6D.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Healthy Cohort - Inclusion Criteria:
We will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis.
Exclusion criteria
129-XeMRI scan
Time frame: through study completion, an average of 1 year
Contact information is provided by the study sponsor or research team.
M.D. Anderson Cancer Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07218939
Pulmonary
Houston, Texas, United States
View Trial DetailsNCT07320703
Breathlessness, Cardiovascular
Groningen, Netherlands
View Trial DetailsNCT07276477
Behavior, Brain Diseases
Uşak, Turkey (Türkiye)
View Trial DetailsNCT07713225
Fear Anxiety, Performance Assessment
Konya, Türkiye, Turkey (Türkiye)
View Trial Details